FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average I	burden							
hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Horn Kinney  (Last) (First) (Middle)  C/O OLEMA PHARMACEUTICALS, INC.  512 2ND STREET, 4TH FLOOR						2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [ OLMA ]  3. Date of Earliest Transaction (Month/Day/Year) 07/12/2021								Relationship of Reporting Person(s) to Issuer heck all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  CHIEF BUSINESS OFFICER				wner specify R
(Street) SAN FRANCI			- 4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	e) X Form	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(Si		Zip)															
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)					ction	ion 2A. Deemed Execution Date,			3. Transaction Code (Instr. ) 8)			i (A) or	or 5. Amount of			n: Direct r Indirect	7. Nature of Indirect Beneficial Ownership	
						(,,,,,	ona "Day" real"		Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	d tion(s)			(Instr. 4)
Common Stock 07/12					2021	2021					5,251	A	\$2.06	4 7,	7,041		D	
Common Stock 07/12/2					2021	2021					3,859	D	\$26.33	(2) 3,	3,182		D	
Common Stock 07/12/2				2021	.021			S <sup>(1)</sup>		1,392	D	\$27 <sup>(3</sup>	1,790			D		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Transaction of Expiration Date Amount of Derivative derivative Ownership of Indirect Security or Exercise (Month/Day/Year) if any Code (Instr. Derivative (Month/Day/Year) Securities Security Securities Form: Beneficial																	
· · · · · ·	Derivative Security		,	,,	"		Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					Derivative (Instr. 3 ar	Security	,	Owned Following Reported Transactio (Instr. 4)	,	or Indirect (I) (Instr. 4)	(Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$2.064	07/12/2021			M			5,251	(4)		06/09/2030	Common Stock	5,251	\$0	183,79	5	D	

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- 2. The weighted average sale price for the transaction reported was \$26.33, and the range of prices were between \$25.74 and \$26.72. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- 3. The weighted average sale price for the transaction reported was \$27.00, and the range of prices were between \$26.80 and \$27.16. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- 4. The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date

/s/ John B. Moriarty, Jr., 07/13/2021 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.